335150-99-7

Basic information

• Product Name: N-(2-hydroxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide
• Synonyms: N-(2-hydroxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide
• CAS NO: 335150-99-7
• Molecular Weight: 343.447
• Mol File: 335150-99-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(2-hydroxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-hydroxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide(335150-99-7)
• EPA Substance Registry System: N-(2-hydroxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide(335150-99-7)

Safety Data

• Hazardous Substances Data: 335150-99-7(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 111047-54-2 (S)-methyl 2-((4-methylphenyl)sulfonamido)-2-phenylacetate 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 335151-02-5 N-allyl-N-(2-allyloxy-1-phenyl-2-vinyl-but-3-enyl)-4-methyl-benzenesulfonamide 
• 335151-13-8 2-[(3R,5R,6S)-6-Phenyl-7-(toluene-4-sulfonyl)-1-oxa-7-aza-spiro[4.5]dec-3-yl]-4-trifluoromethoxy-phenol 
• 335151-10-5 (2S,3S)-3-Allyloxy-2-phenyl-1-(toluene-4-sulfonyl)-3-vinyl-1,2,3,6-tetrahydro-pyridine 
• 335151-08-1 N-allyl-4-methyl-N-[phenyl-(2-vinyl-2,5-dihydro-furan-2-yl)-methyl]-benzenesulfonamide 
• 335151-04-7 (5R,6S)-6-Phenyl-7-(toluene-4-sulfonyl)-1-oxa-7-aza-spiro[4.5]deca-3,9-diene 

Relevant articles and documents

A double ring closing metathesis reaction in the rapid, enantioselective synthesis of NK-1 receptor antagonists.

[structure: see text]. The NK-1 receptor antagonist 1 has been prepared in seven steps from phenylglycine methyl ester. The key steps are a double ring closing metathesis reaction of tetraene 7 to prepare spirocycle 6 and a reductive Heck reaction to introduce the aryl moiety. This latter reaction discriminates the olefins of compound 6 and proceeds in a highly regio- and stereoselective manner.